Top

Published in:

Open Access 01-02-2018 | Original Article

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

Authors: Zhenjiang Liu, Thomas Poiret, Oscar Persson, Qingda Meng, Lalit Rane, Jiri Bartek Jr., Julia Karbach, Hans-Michael Altmannsberger, Christopher Illies, Xiaohua Luo, Inti Harvey-Peredo, Elke Jäger, Ernest Dodoo, Markus Maeurer

Published in: Cancer Immunology, Immunotherapy | Issue 2/2018

Abstract

The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1 (n = 38 samples) protein expression in tumor specimens. T-cells from peripheral blood were stimulated with TAAs (synthetic peptides) in IL-2 and IL-7, or using a combination of IL-2, IL-15 and IL-21. CD4⁺ and CD8⁺ T-cells were tested for antigen-specific proliferation by flow cytometry, and IFN-γ production was tested by ELISA. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. We could detect antigen-specific IFN-γ responses in 25% blood samples for NY-ESO-1 and 30% for survivin. NY-ESO-1-expanded T-cells recognized naturally processed and presented epitopes. NY-ESO-1 or survivin expression in glioma represents viable targets for anticancer-directed T-cells for the biological therapy of patients with glioma.

Available only for authorised users

Goodenberger ML, Jenkins RB (2012) Genetics of adult glioma. Cancer Genet 205:613–621. doi:10.1016/j.cancergen.2012.10.009 CrossRefPubMed

Desjardins A, Reardon DA, Peters KB, Threatt S, Coan AD, Herndon JE 2nd, Friedman AH, Friedman HS, Vredenburgh JJ (2011) A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol 105:601–606. doi:10.1007/s11060-011-0627-0 CrossRefPubMed

Hegde M, Bielamowicz KJ, Ahmed N (2014) Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov Med 17:145–154PubMed

Belli F, Testori A, Rivoltini L et al (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20:4169–4180CrossRefPubMed

Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462–1466. doi:10.1158/1078-0432.CCR-04-1737 CrossRefPubMed

Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6:1251–1259PubMed

Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20:267–275. doi:10.1016/j.smim.2008.04.001 CrossRefPubMedPubMedCentral

Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H (2006) Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 66:5883–5891. doi:10.1158/0008-5472.CAN-06-0363 CrossRefPubMed

Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8:2851–2855PubMed

10.

Brown CE, Alizadeh D, Starr R et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:2561–2569. doi:10.1056/NEJMoa1610497 CrossRefPubMedPubMedCentral

11.

Joshi BH, Leland P, Silber J, Kreitman RJ, Pastan I, Berger M, Puri RK (2002) IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br J Cancer 86:285–291. doi:10.1038/sj.bjc.6600034 CrossRefPubMedPubMedCentral

12.

Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584. doi:10.1038/25141 CrossRefPubMed

13.

Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102:571–576. doi:10.1182/blood-2002-08-2554 CrossRefPubMed

14.

Islam A, Kageyama H, Takada N et al (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19:617–623. doi:10.1038/sj.onc.1203358 CrossRefPubMed

15.

Casati C, Dalerba P, Rivoltini L et al (2003) The apoptosis inhibitor protein survivin induces tumor-specific CD8⁺ and CD4⁺ T cells in colorectal cancer patients. Cancer Res 63:4507–4515PubMed

16.

Idenoue S, Hirohashi Y, Torigoe T et al (2005) A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11:1474–1482. doi:10.1158/1078-0432.CCR-03-0817 CrossRefPubMed

17.

Jager E, Gnjatic S, Nagata Y et al (2000) Induction of primary NY-ESO-1 immunity: CD8⁺ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1⁺ cancers. Proc Natl Acad Sci USA 97:12198–12203. doi:10.1073/pnas.220413497 CrossRefPubMedPubMedCentral

18.

Jager D, Unkelbach M, Frei C, Bert F, Scanlan MJ, Jager E, Old LJ, Chen YT, Knuth A (2002) Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immun 2:5PubMed

19.

Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM (1999) Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5:335–341PubMed

20.

Natsume A, Wakabayashi T, Tsujimura K et al (2008) The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122:2542–2553. doi:10.1002/ijc.23407 CrossRefPubMed

21.

Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856–860. doi:10.1002/ijc.1282 CrossRefPubMed

22.

Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354CrossRefPubMedPubMedCentral

23.

Lagrelius M, Jones P, Franck K, Gaines H (2006) Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. Cytokine 33:156–165. doi:10.1016/j.cyto.2006.01.005 CrossRefPubMed

24.

Alvarez-Corrales N, Ahmed RK, Rodriguez CA et al (2013) Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-gamma and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras. BMC Infect Dis 13:125. doi:10.1186/1471-2334-13-125 CrossRefPubMedPubMedCentral

25.

Gaines H, Andersson L, Biberfeld G (1996) A new method for measuring lymphoproliferation at the single-cell level in whole blood cultures by flow cytometry. J Immunol Methods 195:63–72CrossRefPubMed

26.

Magalhaes I, Vudattu NK, Ahmed RK et al (2010) High content cellular immune profiling reveals differences between rhesus monkeys and men. Immunology 131:128–140. doi:10.1111/j.1365-2567.2010.03284.x PubMedPubMedCentral

27.

Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM (2011) Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med 9:192. doi:10.1186/1479-5876-9-192 CrossRefPubMedPubMedCentral

28.

Odunsi K, Jungbluth AA, Stockert E et al (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63:6076–6083PubMed

29.

Widenmeyer M, Griesemann H, Stevanovic S et al (2012) Promiscuous survivin peptide induces robust CD4⁺ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 131:140–149. doi:10.1002/ijc.26365 CrossRefPubMed

30.

Sahin U, Koslowski M, Tureci O et al (2000) Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6:3916–3922PubMed

31.

Corso CD, Ali AN, Diaz R (2011) Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res 1:390–412PubMedPubMedCentral

32.

Fujiwara S, Wada H, Kawada J et al (2013) NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer 108:1119–1125. doi:10.1038/bjc.2013.51 CrossRefPubMedPubMedCentral

33.

Uemura N, Kodama S, Nomi N, Okamoto T, Suzuki M (2010) Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients. Acta Otolaryngol 130:959–965. doi:10.3109/00016480903555416 CrossRefPubMed

34.

Robbins PF, Kassim SH, Tran TL et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21:1019–1027. doi:10.1158/1078-0432.CCR-14-2708 CrossRefPubMed

35.

Everson RG, Antonios JP, Lisiero DN et al (2016) Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol 18:368–378. doi:10.1093/neuonc/nov153 CrossRefPubMed

36.

Gupta A, Nuber N, Esslinger C et al (2013) A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immun 13:3PubMedPubMedCentral

37.

Dutoit V, Taub RN, Papadopoulos KP et al (2002) Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813–1822. doi:10.1172/JCI16428 CrossRefPubMedPubMedCentral

38.

Kitahara T, Watanabe O, Yamaura A, Makino H, Watanabe T, Suzuki G, Okumura K (1987) Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol 4:329–336CrossRefPubMed

39.

Tsurushima H, Liu SQ, Tuboi K, Matsumura A, Yoshii Y, Nose T, Saijo K, Ohno T (1999) Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res 90:536–545CrossRefPubMed

40.

Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S (2000) T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:2209–2218PubMed

41.

Rosenberg SA, Lotze MT, Muul LM et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492. doi:10.1056/NEJM198512053132327 CrossRefPubMed

42.

Hayes RL, Koslow M, Hiesiger EM et al (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840–852CrossRefPubMed

43.

Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, DePriest MC (2009) Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 32:914–919. doi:10.1097/CJI.0b013e3181b2910f CrossRefPubMed

44.

Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, Gudeman S, Varia MA (1999) Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45:141–157CrossRefPubMed

45.

Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1–30. doi:10.1016/S0065-230X(06)95001-5 CrossRefPubMed

46.

Kanwar RK, Cheung CH, Chang JY, Kanwar JR (2010) Recent advances in anti-survivin treatments for cancer. Curr Med Chem 17:1509–1515CrossRefPubMed

47.

Chapuis AG, Thompson JA, Margolin KA et al (2012) Transferred melanoma-specific CD8⁺ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci USA 109:4592–4597. doi:10.1073/pnas.1113748109 CrossRefPubMedPubMedCentral

48.

Butler MO, Friedlander P, Milstein MI et al (2011) Establishment of antitumor memory in humans using in vitro-educated CD8⁺ T cells. Sci Transl Med 3:80ra34. doi:10.1126/scitranslmed.3002207 CrossRefPubMed

49.

Alves NL, Arosa FA, van Lier RA (2005) IL-21 sustains CD28 expression on IL-15-activated human naive CD8⁺ T cells. J Immunol 175:755–762CrossRefPubMed

50.

Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H, Busch DH (2007) A single naive CD8⁺ T cell precursor can develop into diverse effector and memory subsets. Immunity 27:985–997. doi:10.1016/j.immuni.2007.10.012 CrossRefPubMed

51.

Uhlin M, Gertow J, Uzunel M et al (2012) Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 55:1064–1073. doi:10.1093/cid/cis625 CrossRefPubMed

Title: NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
Authors: Zhenjiang Liu
Thomas Poiret
Oscar Persson
Qingda Meng
Lalit Rane
Jiri Bartek Jr.
Julia Karbach
Hans-Michael Altmannsberger
Christopher Illies
Xiaohua Luo
Inti Harvey-Peredo
Elke Jäger
Ernest Dodoo
Markus Maeurer
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 2/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2066-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells

A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer

A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients

Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer